About vanda pharma - VNDA
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
VNDA At a Glance
Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Washington, District of Columbia 20037
| Phone | 1-202-734-3400 | Revenue | 216.11M | |
| Industry | Pharmaceuticals: Major | Net Income | -220,474,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 8.72% | |
| Fiscal Year-end | 12 / 2026 | Employees | 533 | |
| View SEC Filings |
VNDA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.405 |
| Price to Book Ratio | 1.593 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.928 |
| Enterprise Value to Sales | 1.242 |
| Total Debt to Enterprise Value | 0.047 |
VNDA Efficiency
| Revenue/Employee | 405,450.281 |
| Income Per Employee | -413,647.28 |
| Receivables Turnover | 3.96 |
| Total Asset Turnover | 0.377 |
VNDA Liquidity
| Current Ratio | 2.392 |
| Quick Ratio | 2.379 |
| Cash Ratio | 1.818 |
VNDA Profitability
| Gross Margin | 90.722 |
| Operating Margin | -69.951 |
| Pretax Margin | -64.157 |
| Net Margin | -102.022 |
| Return on Assets | -38.506 |
| Return on Equity | -50.934 |
| Return on Total Capital | -64.882 |
| Return on Invested Capital | -50.057 |
VNDA Capital Structure
| Total Debt to Total Equity | 3.858 |
| Total Debt to Total Capital | 3.714 |
| Total Debt to Total Assets | 2.581 |
| Long-Term Debt to Equity | 2.16 |
| Long-Term Debt to Total Capital | 2.08 |